DBD Diebold Nixdorf Forecast, Technical & Fundamental Analysis

DBD's Stochastic Oscillator entering overbought zone

The Stochastic Oscillator for DBD moved into overbought territory on January 13, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for DBD moved out of overbought territory on December 29, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 13, 2026. You may want to consider a long position or call options on DBD as a result. In of 44 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DBD just turned positive on January 13, 2026. Looking at past instances where DBD's MACD turned positive, the stock continued to rise in of 23 cases over the following month. The odds of a continued upward trend are .

DBD moved above its 50-day moving average on January 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in of 169 cases, the price rose further within the following month. The odds of a continued upward trend are .

DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 128 cases where DBD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DBD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.276) is normal, around the industry mean (11.478). P/E Ratio (52.052) is within average values for comparable stocks, (109.296). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.778). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (0.715) is also within normal values, averaging (57.596).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.